ERBB2 and breast carcinoma: Preliminary studies suggested that a higher dose of trastuzumab is necessary for effective treatment response, as the BCM–3472 PDX model of HER2+ breast cancer was insensitive to the 4 mg/kg dose, but responsive to doses of 10 mg/kg or greater.